logo

menu closed
top

THE SCIENCE

PLATFORM TECHNOLOGY

ONCOZEN’s Platform Technology: Chaperone-Mediated Protein Degradation (CMPD)

Revolutionizing Targeted Protein Degradation (TPD) Targeted protein degradation (TPD) has emerged as a transformative therapeutic approach in small molecule drug development, addressing diseases such as cancer driven by the aberrant expression of disease-causing proteins.

ONCOZEN’s CMPD Technology is an innovative and novel addition to the TPD landscape. CMPD leverages cellular degradation pathways, particularly the ubiquitin-proteasome system (UPS), through the mediation of chaperone complexes. Chaperones play a pivotal role in ensuring proper protein folding, stability, and activation, while also recognizing misfolded proteins and directing them toward degradation via the UPS. The unique ability of chaperones to target proteins for degradation is facilitated by their interaction with diverse E3 ubiquitin ligases in the body, enabling the degradation of a wide variety of disease-causing proteins.

How OZ Degraders Work & Advancing Drug Discovery with Cutting-Edge Technology

Our proprietary OZ Degraders are designed as bifunctional molecules with two key components:
A chaperone-binding moiety that is recognized by the chaperone complex.
A small molecule moiety that selectively binds to the target protein.
These components are chemically linked, enabling the chaperone complex to promote interactions between the cellular degradation machinery (UPS), providing a precise and targeted therapeutic approach.

ONCOZEN has developed proprietary novel chaperone-binding molecules and a library of diverse linkers, enabling the creation of highly optimized OZ Degraders.
Our robust platform integrates artificial intelligence to streamline drug design, accelerating the validation and optimization of candidates.

Customized Solutions with ONCOZEN’s CMPD Platform

ONCOZEN’s platform technology offers flexible solutions for potential partners, including co-development and service partnerships, to develop TPD drugs targeting novel proteins implicated in cancer and other diseases with significant unmet medical needs.
By collaborating with ONCOZEN, partners can leverage our cutting-edge CMPD technology to address complex biological challenges and bring innovative therapies to market.